ImpediMed

Executive Summary

ImpediMed Ltd. is a commercial-stage digital health company specializing in bioimpedance spectroscopy (BIS) technology. Its lead product, the SOZO platform, provides non-invasive, rapid measurements of fluid status and body composition, enabling early detection and monitoring of lymphedema, heart failure, and metabolic conditions. The device is FDA-cleared and used in clinical settings and wellness programs. ImpediMed has established distribution in the U.S., Australia, and select international markets, with a growing base of recurring revenue from SOZO device sales and SaaS subscriptions. The company’s value proposition lies in replacing traditional tape-measure and subjective assessments with objective, data-driven insights, potentially reducing hospital readmissions for heart failure and improving outcomes for cancer-related lymphedema. With an aging population and increasing prevalence of chronic diseases, ImpediMed is well positioned to capture share in the fluid management and metabolic health monitoring markets. Recent efforts have focused on expanding clinical evidence, securing reimbursement codes, and forging partnerships with hospital systems and corporate wellness providers. The company’s path to profitability hinges on scaling adoption and demonstrating cost savings to payers.

Upcoming Catalysts (preview)

• Q3 2026Expanded Medicare reimbursement for lymphedema monitoring70% success
• Q3 2026Positive results from heart failure remote monitoring study60% success
• TBDNew strategic partnership with a major hospital network50% success